David Moatazedi

Person

Last mentioned: Mar 5, 2026

Timeline

  1. Anticipated FDA Approval

    Expected regulatory clearance for the first Evolysse filler products.

  2. Commercial Launch

    Planned U.S. launch of the Evolysse filler portfolio to aesthetic injectors.

  3. Q4 Earnings

    Company reports record revenue and market share for Jeuveau.

  4. Filler Partnership

    Evolus expands partnership with Symatese for the Evolysse dermal filler line.

Stories mentioning David Moatazedi 1

pharma Neutral

Evolus Q4 2025: Jeuveau Market Share Surges as Dermal Filler Launch Approaches

Evolus, Inc. reported strong Q4 2025 results, driven by the continued market share expansion of its flagship neurotoxin, Jeuveau, and progress in its international rollout. The company remains on track to transform into a multi-product aesthetics platform with the anticipated 2026 launch of its Evolysse dermal filler line.

4 sources